Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Autoimmune cytopenias" to "[[Autoimmune cytopenia") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Autoimmune cytopenias medications" to "Category:Autoimmune cytopenia medications") |
||
| Line 21: | Line 21: | ||
[[Category:Aplastic anemia medications]] | [[Category:Aplastic anemia medications]] | ||
| − | [[Category:Autoimmune | + | [[Category:Autoimmune cytopenia medications]] |
[[Category:Castleman disease medications]] | [[Category:Castleman disease medications]] | ||
[[Category:Erdheim-Chester disease medications]] | [[Category:Erdheim-Chester disease medications]] | ||
Revision as of 19:16, 1 March 2019
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Also known as
- Code names: AY 22989, SILA 9268A, SLM, WY-090217
- Generic names: RAPA, rapamycin
- Brand name: Rapamune